Who are 6MP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fludarabine (Flud), Fludarabine (Bayer), Experimental (fludarabine), Mercaptopurine (Purinethol), Nelarabine injection, Fludarabine mono.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/6mp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

6MP — Competitive Intelligence Brief

6MP (6MP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine analog antimetabolite. Area: Oncology.

marketed Purine analog antimetabolite Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

6MP (6MP) — South China Children's Leukemia Group. 6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and DNA replication, leading to cell death in rapidly dividing cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
6MP TARGET	6MP	South China Children's Leukemia Group	marketed	Purine analog antimetabolite	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH)
Fludarabine (Flud)	Fludarabine (Flud)	Technische Universität Dresden	marketed	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase
Fludarabine (Bayer)	Fludarabine (Bayer)	Chinese PLA General Hospital	marketed	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase
Experimental (fludarabine)	Experimental (fludarabine)	French Innovative Leukemia Organisation	phase 3	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase
Mercaptopurine (Purinethol)	Mercaptopurine (Purinethol)	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	phase 3	Purine analog antimetabolite	HGPRT (hypoxanthine-guanine phosphoribosyltransferase); inosinate dehydrogenase
Nelarabine injection	Nelarabine injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Purine analog antimetabolite	Ribonucleotide reductase; deoxyribonucleotide synthesis pathway
Fludarabine mono	Fludarabine mono	German CLL Study Group	phase 3	Purine analog antimetabolite	Ribonucleotide reductase; DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Purine analog antimetabolite class)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chinese PLA General Hospital · 1 drug in this class
French Innovative Leukemia Organisation · 1 drug in this class
German CLL Study Group · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
South China Children's Leukemia Group · 1 drug in this class
Technische Universität Dresden · 1 drug in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 6MP — Competitive Intelligence Brief. https://druglandscape.com/ci/6mp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab